Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baxter Web-Enabled Device Development Starting With Renal Dialysis

This article was originally published in The Gray Sheet

Executive Summary

Baxter projects the growth rate of its renal business will accelerate to 15% "over the next several years" from its current growth rate of "10 to 12%" in part due to web-enabled devices under development.

You may also be interested in...



Baxter Expects To Roughly Double Renal Business By 2005 To $3.5 Bil.

Baxter says it plans to approximately double the size of its renal business to $3.5 bil. annually by 2005, from $1.8 bil. in 2000, increasing the unit's annual growth rate to about 15% over the next several years from the current 9% level, the firm says.

Baxter Expects To Roughly Double Renal Business By 2005 To $3.5 Bil.

Baxter says it plans to approximately double the size of its renal business to $3.5 bil. annually by 2005, from $1.8 bil. in 2000, increasing the unit's annual growth rate to about 15% over the next several years from the current 9% level, the firm says.

Edwards Lifesciences Lifepath AAA Graft Fracture Investigation Ongoing

Edwards Lifesciences is continuing to investigate the cause of fractures detected in the wireform scaffolding of its Lifepath endovascular graft system for treatment of abdominal aortic aneurysms, following discovery of the fractures in two patients treated with the device.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel